BioSpectra to Present at ExcipientFest 2017
Chad Pezoldt graduated from East Stroudsburg University of Pennsylvania in 2014 with a B.S. in Biochemistry and a B.S. in Chemical Biotechnology. He joined BioSpectra as a Quality Control Analyst performing and developing analytical methods. He recently transitioned from his role as the Quality Control Manager having extensive oversight of the testing, analysis and approval of Excipients and Active Pharmaceutical Ingredients to Compliance Manager. Chad is also attending Johns Hopkins University pursuing his M.S. in Regulatory Science in an effort to remain current with the evolving regulatory responsibilities in the pharmaceutical industry.
BioSpectra will be participating in this year’s ExcipientFest which features in-depth technical talks on Excipient Technology, New Drug Applications and Regulatory Issues from the industry’s top-pharmaceutical experts. The conference will be held on April 25-26th in Providence, Rhode Island. BioSpectra’s Compliance Manager, Chad Pezoldt will be presenting to the conference on “Ensuring Patient Safety through Appropriate Impurity Evaluation”. For more information on ExcipientFest, please follow this link http://www.excipientfest.com.
Ensuring Patient Safety through Appropriate Impurity Evaluation
The presence of undetected impurities in drug products can lead to devastating side effects. For example, Diethylene Glycol (DEG) as an impurity has troubled the drug product industry for nearly 75 years. DEG has been used as a low cost but toxic substitute for glycerin and has directly caused the death of hundreds of children and adults. Tragedies such as these are preventable.
The scope of this presentation is to discuss a scientific, collaborative and unbiased approach to the responsible evaluation of pharmaceutical ingredients. The evaluation must begin internally and extend to the outer boundaries of a drug product’s supply chain. A weak approach to the evaluation of ingredient impurities can potentially adulterate the entire chain.
Investigation of possible impurities begins with a realistic evaluation of a firm’s manufacturing environment including historical factors and inherent properties of the product and its raw materials. Furthermore, the investigation must include in depth evaluations of raw material manufacturing paths and supplier questionnaires.
These factors must be compiled to design a comprehensive impurity profile that, when combined with proper analytical techniques, supports industry’s assurance of patient safety.